ADPT — Adaptive Biotechnologies Corporation

Adaptive Biotechnologies (ADPT) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $71.7 million, a 63% increase year-over-year.
• Full Year Revenue: $277 million, representing 55% growth year-over-year.
• Adjusted EBITDA: Positive $4.1 million in Q4 compared to a loss of $16.4 million in Q4 2024; full year adjusted EBITDA was $12.2 million, up from a loss of $80.4 million in 2024.
• Net Loss: $13.6 million for Q4 and $59.5 million for the full year.
• Cash Position: $227 million at year-end, with a 68% reduction in cash burn.

2. Strategic Updates and Business Highlights

• MRD Business Growth: Revenue grew 46% year-over-year, with clonoSEQ clinical testing revenue increasing 64%. Test volumes reached a record of 30,038 in Q4, up 43% year-over-year.
• Integration and Coverage: Successful integration of clonoSEQ into Flatiron's Onco EMR and first Medicare coverage for recurrence monitoring in mantle cell lymphoma (MCL).
• Pricing Strategy: Average selling price (ASP) increased to $1,307 per test, with expectations to reach $1,400 in 2026.
• Immune Medicine Progress: Scaled TCR antigen data and secured two data partnerships with Pfizer, focusing on data licensing and target discovery for rheumatoid arthritis.
• Operational Efficiency: Sequencing gross margin improved to 71% in Q4, up from 59% year-over-year.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: MRD revenue expected between $255 million and $265 million, implying 22% growth year-over-year.
• Adjusted EBITDA: Anticipated to be positive by the end of 2026.
• Volume Growth Expectations: ClonoSEQ test volumes projected to grow over 30% year-over-year, with a focus on increasing blood-based testing to over 50% of total MRD volume.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Concerns regarding a competitor's flow cytometry product claiming sensitivity comparable to clonoSEQ, which may impact market share.
• Execution Risks: Potential risks associated with the timing and outcomes of ongoing payer contract negotiations that could affect ASP growth.
• Market Dynamics: Seasonal impacts on testing volumes, particularly in Q1 due to weather-related delays, could affect short-term performance.

5. Notable Q&A Insights

• Volume Trends: Management acknowledged potential seasonality in testing volumes and confirmed a strong start to Q1 despite weather-related challenges.
• Market Penetration Strategy: Emphasis on leveraging existing strengths in multiple myeloma to drive growth in DLBCL, with ongoing efforts to enhance physician adoption and testing frequency.
• ASP Growth Factors: ASP growth is contingent on successful negotiations with large payers and the overall performance of MRD testing across different indications.
• Immune Medicine Focus: The strategy is shifting towards monetizing large-scale proprietary data, with expectations for continued partnerships and data licensing opportunities.

Overall, Adaptive Biotechnologies demonstrated strong financial performance in 2025, with significant growth in its MRD business and strategic advancements in its Immune Medicine segment. However, the company faces competitive pressures and execution risks that could impact future performance.